Low density lipoproteins (LDL) have long been recognized as a potential delivery system for exogenous agents. Imaging agents or drugs can be attached to LDL through surface loading, protein loading or core loading methods. The LDL delivery system has received considerable attention particularly among cancer biologists as it was observed that numerous cancers over-express the low density lipoprotein receptor (LDLR). In this paper we investigate the utility of LDL to transport optical imaging contrast agents for caner detection. The method of loading fluorophores into the core of LDL is attractive as it behaves like an activatable contrast agent. Surface and protein labeled methods also prove to be effective strategies for tracing LDL nanoparticle activity. The strengths and limitations of the LDL carrier system are discussed and novel approaches for imaging cancer with LDL nanoparticles are highlighted.
INTRODUCTION
The potential of using low density lipoproteins (LDL) as carriers for targeted delivery of diagnostic and therapeutic agents to tumor cells has long been recognized 1, 2 . Early observations identified that several hydrophobic and basic drugs passively associate with plasma lipoproteins 3 , in addition, drug-lipoprotein complexes were shown to have favorable pharmacologic profiles for drug delivery 4 . These findings were particularly attractive to cancer biologists as it was also observed that numerous cancers over-express the low density lipoprotein receptor (LDLR) 5 . The up-regulated levels of this receptor are believed to provide cancer cells with necessary lipid substrates needed for active membrane synthesis. In fact, tumor sequestration of plasma LDL cholesterol has been suggested to explain the low levels of circulating total and LDL cholesterol observed in patients with malignant disease 6 . These finding have led many investigators to explore the possibility of exploiting LDL as a delivery vehicle for cancer diagnostics and therapeutics. Experimentalists in the field of nuclear medicine were the first to demonstrate the utility of contrast agents conjugated LDL for imaging 7, 8 . Radionuclides attached to apoB-100 protein of LDL served as a viable tracers for LDLR activity 9, 10 .
The high sensitivity of this modality allows a few molecules of radiotracers to be attached to the LDL particle thus preserving the functional activity of LDL. From theses studies preferential accumulation of the radio tracer was observed in the LDLR expressing tissues. While this approach demonstrated the merit of utilizing the LDLR system to monitor lipoprotein metabolism, the low spatial resolution of these images impaired anatomical demarcation of tissue or tumor boundaries. Since these studies were performed alternate approaches of incorporating diagnostic probes on to LDL have been pursued, they include intercalation of amphiphilic agents onto the surface of LDL or reconstitution of hydrophobic compounds into the LDL core [11] [12] [13] [14] . These approaches offer the flexibility of attaching contrast agents of other modalities to LDL without compromising the functional integrity of this endogenous carrier. Optical imaging is quickly emerging as an attractive diagnostic modality in biomedical research. This technique has a number of advantages which include low cost, easy storage of reagents, and lack of radioactivity (45). Furthermore, because a fluorophore is not annihilated upon radiation emission as is a radiotracer, the same probe can be excited repeatedly thereby providing higher sensitivity for imaging. In addition, owing to relatively low tissue absorbance and minimal autofluorescence, NIR light (700-900 nm) can penetrate several centimeters of tissue without the harmful radiation effects of gamma rays, Xrays, or ultraviolet light. The most commonly used optical probe in the NIR spectral window is Indocyanine Green (ICG, excitation 780 nm, emission 830nm), an FDA-approved carbocyanine dye for imaging (46). Because ICG has a long track record in human use, it may be readily brought to clinical trial as an NIR contrast agent when it is attached to biologically active compounds. Here we report the advances made by our laboratory in utilizing LDL as a diagnostic platform for optical imaging of cancer. We highlight the strengths of the LDL carrier system as well as its limitations and discuss some novel approaches for lipoprotein based imaging of cancer.
METHODOLOGY

Low-Density Lipoprotein
LDL was isolated from fresh plasma of healthy donors by sequential ultracentrifugation as described previously by Lund-Katz et al. 15 .
Preparation of fluorescent dye: DiR-BOA (1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide bis-oleate).
Synthesis of N-Oleyl 2,3,3-trimethyl-3H-indole Bromide.
Ortho-dichlorobenzene (ODB) (20 ml) was added to 477.7 mg (3.0 mmol) of 2,3,3-trimethyl-3H-indole and 994 mg (3.0 mmol) of oleyl bromide and the solution was stirred at 100 ºC under argon for 30 hours. ODB was removed by high vacuum and the residue was purified by column chromatography (silica gel) with dichloromethane/methanol (V:V=92:8) as the eluent.
Synthesis of DiR-BOA. Acetic anhydride (Ac 2 O) (0.50 mmol) was added dropwise to a stirring suspension of glutaconaldehyde dianilide monohydrochloride (142 mg, 0.50 mmol) and 1.0 mmol of DIPEA in 5 ml DCM (dichloromethane) under argon at room temperature. After 20 min, the solution became clear. The resulting clear solution was stirred for an additional 2 hrs and then concentrated. The residue was dissolved in 3 ml methanol and was added dropwise to a refluxing solution of N-oleyl 2,3,3-trimethyl-3H-indole bromide (420 mg, 0.86 mmol) in 10 ml methanol and NaOAc (164 mg, 2.0 mmol). The mixture was refluxed under argon for 20 hours and concentrated. The residue was then purified with column chromatography (silica gel) using 3% methanol in dichloromethane as eluent to get dark green product DiR-BOA (ex. 748nm, em. 782nm).
Core loading fluorescent label rDIR-BOA-LDL: Reconstitution of the fluorescent tracer, DiR-BOA, into LDL was performed similar to the method of Krieger et al. Briefly, LDL (1.9 mg) was lyophilized with 25 mg starch, and then extracted three times with 5 mL of heptane at -5°C. Following aspiration of the last heptane extract, 0.6mg of DiR-BOA and 5.4mg of Triolein (~1mg/µl) was added in 200 µL of benzene. After 90 min at 4°C, benzene and any residual heptane were removed under a stream of N 2 in an ice salt bath for about 45 min. The r-DiR-BOA-LDL was solubilized in 10 mM Tricine, pH 8.2, at 4°C for 24 h and starch was removed by centrifugation. The reconstituted LDL was stored under an inert gas at 4°C. The protein content of the specimen was determined by the Lowry method and probe concentration was calculated based on its absorption spectrum. Probe/protein molar ratio was then calculated using the molecular mass of the ApoB-100 protein (514 kDa) knowing that one LDL particle contains only one ApoB-100.
Surface loading fluorescent label (DIR-LDL)
The lipophilic near infrared dye DIR was purchased from Molecular Probes (Eugene, OR) and incorporated into the surface of LDL using the method described in the literature 16, 17 . The molar ratio of this NIR dye to apoB-100 protein (DiR:LDL) was approximately 10:1. This is based on the assumption that apoB-100 was the only protein present with one protein per LDL particle.
Folate receptor targeted LDL (DIR-LDL-FA)
The pH of DiR-LDL solutions (5mL) was increased to 9.4 by dialyzing against 0.1M NaH 2 PO 4 , 0.1M H 3 BO 3 buffer at 4°C overnight. Folate-N-Hydroxysuccinimide ester (FA-NHS) was synthesized as described by Zheng et al. 2005 . FA-NHS in anhydrous DMSO was slowly added to this LDL solution (molar ratio of FA-NHS/LDL = 200:1). The reaction mixture was kept at 4°C for 40h, then centrifuged at 500rpm at 4°C to remove any precipitate from degraded LDL and subsequently dialyzed against EDTA buffer (0.3mM EDTA, 0.9% NaCl, pH 7.4) at 4°C overnight. Over the course of the dialysis, the pH of the DiR-LDL-FA solution returned to 7.4, and unreacted FA-NHS starting materials were eliminated. This dialysis procedure was repeated until no evidence of free FA was detectable by UV spectrophotometry. The resulting product, DiR-LDL-FA, was obtained with a yield of 75%. The number of FA molecules conjugated to each LDL nanoparticle was determined by UV spectrophotometry as described previously.
Protein fluorescent labeling (protein loading)
To synthesize the protein labeled FA-NIR664-LDL folate-N-Hydroxysuccinimide ester (FA-NHS), NIR664-succinimide and LDL were incubated at a molar ratio of 200:40:1 respectively under basic conditions (pH 9.0) as described above. The product was purified by dialysis with EDTA buffer.
Experimental Animals and Induction of Tumor Xenografts
Adult female nude mice (average 20g) were permitted ad libitum access to food and water throughout the study. To induce solid tumors, 10 6 HepG 2 (over-express LDLR) or KB (FR positive) and HT1080 (FR negative) cells were injected subcutaneously into the respective right and left lower flanks of the nude mice. Tumors xenografts were grown to 3-5mm before in vivo imaging.
In Vivo Imaging
In vivo fluorescence imaging was performed with a Xenogen IVIS Lumina imaging system (Hopkinton, MA, USA). Fluorescent images were acquired with following settings: ICG filter (ex=710-760nm, em=810-875nm), stage B, small Binning, fstop/2, lamp high level, and exposure time of 6 sec.
RESULTS
The present paper demonstrates that LDL is a versatile carrier capable of being functionalized to ferry exogenous compounds. As shown in Figure 1 , diagnostic or therapeutic agents can be incorporated into LDL via covalent attachment to the amino acid residues of apoB-100 protein of LDL (protein loading), through intercalation into the phospholipid monolayer of LDL (surface loading), and last via substitution of agents into the lipid core of LDL (reconstitution/core loading). 
DiR-LDL-FA:
In vivo distribution of DiR-LDL-FA (molar ratio 8:1:105 respectively) in dual tumor (KB/HT1080) bearing nude mice was monitored with a Xenogen IVIS imager (Figure 4 ). After injection of the DiR-labeled LDL particle, the fluorescent label quickly washed in (see 25min image) and washed out from the HT1080 tumor (see 2.5h image), accumulation is only observed in the folate positive tumor (see 24h image). These findings were further validated by the biodistribution assay as both tumors (KB and HT1080) and various organs (liver, kidney, spleen, muscle, gut, heart and adrenal) were harvested and imaged separately using the Xenogen instrument. As shown in Figure 5 , KB tumor (FR positive) has much higher DiR-LDL-FA uptake than HT1080 tumor (FR negative). The average intensity of DiR-LDL-FA in KB is slightly less than liver and spleen, comparable to gut but much higher than adrenal. Muscle, kidney and heart essentially have no nanoparticle uptake.
Protein Loading:
The third cargo-loading method involves the direct conjugation of probes to the Lys residues of apoB-100. This method has serious limitation for LDLR targeting since in most cases, the probe/LDL ratio must be kept low to avoid disrupting the LDL/LDLR interaction. However, in this rerouting approach LDL/LDLR interactions are no longer desired. Conjugating both NIRF probes and folate targeting molecules on the apoB-100 provides a permanent optical tracer to monitor the (FA)LDL. The molar ratio of FA-NIR664-LDL was 60:30:1 respectively. As shown in Figure 6 , in vivo NIRF imaging clearly demonstrated the selective uptake of (FA/NIR664)-LDL in KB (FR positive) tumors further validating the LDL rerouting strategy.
DISCUSSION
The high carrying capacity of LDL makes it an attractive nanocarrier for exogenous compounds. In this paper we have demonstrated that LDL can effectively ferry payloads of NIR fluorescent contrast agents via reconstitution (core-loading), intercalation (surface-loading) and protein labeling (protein-loading) methods. The behavior of the fluorophore and pattern of fluorescence differs depending on the choice of labeling. For the core-loaded r-DIRBOA-LDL particles low levels of fluorescence is initially emitted due significant self quenching of the core-loaded fluorochrome. Enhanced fluorescence is achieved when the fluochromes are released from the LDL core. Hence for in vivo applications r-DIRBOA-LDL can be considered and activateable reporter of LDLr activity. Conversely intercalated and protein labeled fluorophores are widely distributed over the surface of LDL and hence are in a constant 'on' state.
In vivo experiments went on to demonstrate this phenomenon. In the animals treated with r-DIRBOA-LDL weak fluorescence was observed in the early post injection period then it gradual builds over the course of the experiment. Regions of high fluorescent intensity (abdomen and HepG2 tumor) are indicative of active uptake and degradation of the LDL particle in LDLR expressing tissues. For the animals that received surface or protein labeled LDL moderate fluorescence is seen throughout the animal as a 'flush' immediately after injection. For these probes the regions of higher fluorescence detected over time are reflective of accumulation rather than activation. Regardless of the type of labeling LDL nanoparticles are actively taken up by LDLR expressing cells.
Although LDL based therapeutic and imaging agents do effectively target and accumulate in cancer cells this platform suffers from limited tumor selectivity over normal tissues. The liver, adrenal and reproductive organs all express high levels of LDLR 18, 19 and thus would effectively compete and be exposed to high levels of the administered drug or imaging agent. Even though the LDLR expression levels in these tissues may be modulated by the concomitant use of steroids or dietary fats 20, 21 , the down regulation of LDLR is not absolute and the extent this protective effect is uncertain. In addition, the scope for potential LDL based applications in cancer medicine is limited by the narrow purview of LDLR-positive tumors. Undoubtedly, broadening the utility of the LDL base platform to a wider range of tumor types would be an important advance for nanomedicine. We have recently reported that LDL particles can be redirected from its native receptors to alternate surface receptors or epitopes 22 . The redirecting strategy is based on the chemistry of the exposed active lysine residues in apoB-100. These residues play a central role in recognition and binding of LDL to LDLR, thus conjugation of homing ligands to the ε-amino groups of these lysine residues effectively abolishes the affinity of the LDL particle for LDLR and simultaneously redirects the particle to alternate receptors. Proof of the redirection strategy was demonstrated using folic acid (FA) modification of apoB-100 to redirect the LDL particle to the folate receptor (FR) 22 . The accumulation of fluorescent signal in the KB tumor xenograft over that of the HT1080 validates the merit of this redirection strategy for in vivo applications. Although we have shown that we can achieve FR targeting with the LDL nanoparticle competitive uptake processes (RES and exchangeable apoproteins) by the liver and spleen still occurs. Efforts are currently underway in our lab to devise methods to overcome these competitive processes. Pegylation of the LDL nanoparticle may provide one means of overcoming high uptake by the RES. Alternatively, utilizing a different lipoprotein base particle, such as HDL, may improve the nanoparticle kinetic and distribution profile.
Another important hurdle one encounters when using LDL based carriers is the need to isolate LDL from fresh donor plasma. Hence large scale preparation of LDL nanocarriers for clinical applications is severely hindered. Relying on donor plasma to acquire LDL is problematic because LDL samples vary from batch to batch, methods for isolating LDL are lengthy (up to 48 hours) and large quantities of LDL are difficult to attain. Furthermore, isolated LDL can only be stored for finite periods before aggregation and degradative processes compromise the integrity of the LDL sample. As a result of these limitations attempts have been made to prepare synthetic LDL like particles consisting of a phospholipid/cholesterol ester microemulsion and apoB-100 (the LDLR binding component of LDL). Difficulties also plague this endeavor due the size and complexity of the apoB-100 protein 23 . Furthermore apoB-100 is highly insoluble in aqueous solution making it difficult to work with. In addition, these problems are still compounded by the difficulties of having to isolate apoB-100 from donor plasma. To address this problem an elegant yet simple approach of Nikanjam et al. demonstrated that synthetic LDL like particles can be prepared from a lipid emulsion and a synthetic bifunctional 29 amino acid peptide which contains a lipid binding motif and the LDLR binding domain 24 . These LDL like particles were shown to mimic the behavior of native LDL and target the LDLR on carcinoma cells. The opportunity of having an LDL based drug delivery system free from the confines of plasma derived components may finally be attained by the synthetic nLDL technology. In addition if the redirection strategy can also be applied to synthetic nLDL particles one would drastically broaden the potential utility of the nLDL based delivery system to even wider range of tumor types for detection and treatment. The advances this new technology ushers in may allow the potential of lipoprotein based delivery systems to be realized in clinical medicine.
